TALWIN 50
LOE ApproachingNDAORALTABLETPriority Review
Approved
Feb 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALWIN 50 is an oral small-molecule tablet approved in 1969 by Sanofi. The specific indication and mechanism of action are not publicly detailed in available data, limiting assessment of therapeutic positioning. This legacy product represents a mature asset in the company's portfolio.
LOE Approaching
With LOE approaching and no linked jobs currently identified, this product faces declining commercial relevance and likely team contraction or realignment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE, TALWIN 50 represents a low-opportunity career environment. Assignment to this product typically indicates maintenance of legacy franchise rather than growth potential or skill development.
Brand ManagerField Sales Representative
Worked on TALWIN 50 at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.